UM

Browse/Search Results:  1-10 of 38 Help

Selected(0)Clear Items/Page:    Sort:
Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018,Volume: 838,Page: 41-52
Authors:  Yang, Zheng;  Zhang, Shao-Lin;  Hu, Xiaohui;  Tam, Kin Yip
Favorite  |  View/Download:12/0  |  Submit date:2018/10/30
Dichloroacetophenone  Epidermal growth factor receptor  Tyrosine kinase inhibitor  Synergism  Hypoxia  Oxidative phosphorylation  
Periplaneta americana Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats by Keap1/Nrf-2 Activation, Intestinal Barrier Function, and Gut Microbiota Regulation Journal article
FRONTIERS IN PHARMACOLOGY, 2018,Volume: 9
Authors:  Ma, Xuewei;  Hu, Yichen;  Li, Xin;  Zheng, Xiaoting;  Wang, Yitao;  Zhang, Jinming;  Fu, Chaomei;  Geng, Funeng
View  |  Adobe PDF(4337Kb)  |  Favorite  |  View/Download:286/12  |  Submit date:2018/10/30
Ulcerative Colitis  Periplaneta Americana  16s Rrna  Gut Microbiota  Intestinal Immunity  
Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway Journal article
Oncotarget, 2018,Volume: 9,Issue: 62,Page: 31958-31970
Authors:  Nana Ai;  Cheong-Meng Chong.;  Weiting Chen;  Zhe Hu;  Huanxing Su;  Guokai Chen;  Queenie Wing Lei Wong;  Wei Ge
Favorite  |  View/Download:9/0  |  Submit date:2018/12/11
Angiogenesis  Enos  Huvec  Mapk  Ponatinib  
Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018,Volume: 830,Page: 17-25
Authors:  Zhang, Le-Le;  Feng, Zhe-Ling;  Su, Min-Xia;  Jiang, Xiao-Ming;  Chen, Xiuping;  Wang, Yitao;  Li, Ao;  Lin, Li-Gen;  Lu, Jin-Jian
View  |  Adobe PDF(3226Kb)  |  Favorite  |  View/Download:175/23  |  Submit date:2018/10/30
Nagilactone e  Non-small Cell Lung Cancer  Cyclin B1  Cell Cycle  Apoptosis  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
MOLECULAR NEUROBIOLOGY, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo, Dan;  Zhao, Jia;  Cheng, Yuanyuan;  Lee, Simon Ming-Yuen;  Rong, Jianhui
Favorite  |  View/Download:11/0  |  Submit date:2018/10/31
Parkinson's disease  Neuroprotection  N-propargyl caffeamide (PACA)  NGF/TrkApathway  PI3K/Akt  ERK1/2  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson’s Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
Molecular Neurobiology, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo D.;  Zhao J.;  Cheng Y.;  Lee S.M.-Y.;  Rong J.
Favorite  |  View/Download:2/0  |  Submit date:2018/11/06
ERK1/2  N-propargyl caffeamide (PACA)  Neuroprotection  NGF/TrkA pathway  Parkinson’s disease  PI3K/Akt  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
MOLECULAR NEUROBIOLOGY, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo, Dan;  Zhao, Jia;  Cheng, Yuanyuan;  Lee, Simon Ming-Yuen;  Rong, Jianhui
Favorite  |  View/Download:7/0  |  Submit date:2018/10/30
Parkinson's disease  Neuroprotection  N-propargyl caffeamide (PACA)  NGF/TrkApathway  PI3K/Akt  ERK1/2  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
MOLECULAR NEUROBIOLOGY, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo, Dan;  Zhao, Jia;  Cheng, Yuanyuan;  Lee, Simon Ming-Yuen;  Rong, Jianhui
Favorite  |  View/Download:5/0  |  Submit date:2018/10/30
Parkinson's disease  Neuroprotection  N-propargyl caffeamide (PACA)  NGF/TrkApathway  PI3K/Akt  ERK1/2  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
MOLECULAR NEUROBIOLOGY, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo, Dan;  Zhao, Jia;  Cheng, Yuanyuan;  Lee, Simon Ming-Yuen;  Rong, Jianhui
Favorite  |  View/Download:4/0  |  Submit date:2018/10/31
Parkinson's disease  Neuroprotection  N-propargyl caffeamide (PACA)  NGF/TrkApathway  PI3K/Akt  ERK1/2  
Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B Journal article
NEUROPHARMACOLOGY, 2017,Volume: 126,Page: 12-24
Authors:  Guo, Baojian;  Hu, Shengquan;  Zheng, Chengyou;  Wang, Hongyu;  Luo, Fangcheng;  Li, Haitao;  Cui, Wei;  Yang, Xifei;  Cui, Guozhen;  Mak, Shinghung;  Choi, Tony Chung-Lit;  Ma, Edmond Dik-Lung;  Wang, Yuqiang;  Lee, Simon Ming Yuen;  Zhang, Zaijun;  Han, Yifan
View  |  Adobe PDF(2766Kb)  |  Favorite  |  View/Download:137/5  |  Submit date:2018/10/31
Parkinson's disease  SU4312  Neuroprotection  Myocyte enhancer factor 2D  Monoamine oxidase-B